SCHEMBL4701576

SCHEMBL4701576

O=C1C(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)CCN1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.45
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
SCN9A Q15858 1/20 0.43
LIPE Q05469 4/20 0.43
UCHL1 P09936 1/20 0.43
USP30 Q70CQ3 1/20 0.43
CXCR3 P49682 1/20 0.41
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41
BACE1 P56817 2/20 0.41
DPP4 P27487 2/20 0.41
DPP7 Q9UHL4 2/20 0.41
KCNH2 Q12809 1/20 0.41
DRD2 P14416 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
KCNA5 P22460 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701580 1.00 F10 (0.45) F10KMT2AMEN1SCN9ALIPE
SCHEMBL4698155 0.86 F10 (0.51) F10UCHL1USP30DRD2KCNA5
SCHEMBL4698153 0.86 F10 (0.51) F10UCHL1USP30DRD2KCNA5
SCHEMBL13036937 0.80 MMP2 (0.51) F10KMT2AMEN1UCHL1USP30
SCHEMBL3103549 0.80 MMP2 (0.64) F10UCHL1USP30
SCHEMBL3103544 0.80 MMP2 (0.64) F10UCHL1USP30
SCHEMBL4702643 0.77 MMP2 (0.58) DPP4DPP7KCNH2L3MBTL1
SCHEMBL4702649 0.77 MMP2 (0.58) DPP4DPP7KCNH2L3MBTL1
SCHEMBL29087208 0.72 F10 (0.53) F10
SCHEMBL27225588 0.72 F10 (0.53) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1444202-B1 NOVEL METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2008-10-15 EP disclosed
US-7132434-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2006-11-07 US disclosed
US-20050026990-A1 Novel metalloproteinase ihibitors ASTRAZENECA AB (SE) 2005-02-03 US disclosed
EP-1444202-A1 NOVEL METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2004-08-11 EP disclosed
WO-2003040098-A1 NOVEL METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026990-A1 Novel metalloproteinase ihibitors MMP12, MMP1, MMP16 F10 1336/4885KMT2A 2085/4885MEN1 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.